Filter Results
- View All
- PXV
- Xontogeny
June 18, 2024
Marea Therapeutics Launches with $190 Million to Accelerate a New Generation of Medicines for Cardiometabolic Diseases
April 3, 2024
Neurosterix launches with $63M to Advance Allosteric Modulator Therapeutics for Neurological Disorders
September 27, 2023
Avalyn Raises $175 Million in Oversubscribed Series C Financing to Advance Inhaled Pulmonary Fibrosis Programs into Later Stage Clinical Studies
July 25, 2023
A-Alpha Bio Raises $22.4M in Series A2 to Scale Protein-Protein Interaction Data Platforms and Accelerate Internal Pipeline Development
June 20, 2023
Delve Bio Launches to Commercialize its Metagenomic Sequencing Platform for Infectious Disease Diagnosis
April 13, 2023
TORL BioTherapeutics Launches with $158 Million Series B Financing to Advance Development of Novel Oncology Biologics
March 1, 2023
CARGO Therapeutics Raises $200 Million in Oversubscribed, Upsized Series A Financing to Advance its Pipeline of Next Generation CAR T-Cell Therapies
January 15, 2023
Apogee Therapeutics Launches with $169 Million to Develop Potentially Best-in-Class Therapies for Immunological and Inflammatory Disorders
December 13, 2022
Peroxitech Announces Closing of $25M Series A Financing to Develop Novel Treatment for Acute Lung Injury
November 15, 2021
Sermonix Pharmaceuticals Closes $40 Million Series A3 Financing Round Led by Perceptive Xontogeny Ventures Fund II
May 12, 2021
Perceptive Advisors Closes $515 Million Perceptive Xontogeny Venture Fund II, LP
May 12, 2021
Shifa Launches with Seed Financing to Address Cardiovascular Disease by Developing Orally Bioavailable Drugs for the Treatment of Dyslipidemia
May 12, 2021
Tellus Therapeutics Secures Seed Financing to Develop the First Treatment for Newborns with White Matter Brain Injury
May 12, 2021
Peroxitech Therapeutics Secures Seed Financing to Advance New Treatment of Acute Lung Injury
May 12, 2021
NephroDI Therapeutics Lands Financing to Develop a Treatment for Nephrogenic Diabetes Insipidus, an Orphan Disease
May 12, 2021
Nephraegis Therapeutics Launches with Seed Financing to Develop Small Molecules to Prevent and Treat Acute Kidney Injury (AKI)
October 22, 2020
Gene Therapy Company AavantiBio Launches with $107 Million Series A Financing from Perceptive Advisors, Bain Capital Life Sciences, RA Capital Management and Sarepta Therapeutics
July 21, 2020
Forge Biologics Launches with $40 Million Series A Financing to Manufacture and Develop Gene Therapies
December 10, 2019
Perceptive Advisors Closes Inaugural $210 Million Perceptive Xontogeny Venture Fund to Support Early-Stage Biotech Startups
August 28, 2017
Xontogeny Appoints Industry Veteran Fred Callori as Senior Vice President of Corporate Development
May 18, 2017
Xontogeny, a New Accelerator Operating Company, Launches with a $25 Million Series A Financing to Advance Early Stage Life Sciences Technology through Clinical Proof-of-Concept
